ホーム>>Signaling Pathways>> Neuroscience>> GABA Receptor>>PK 11195

PK 11195 (Synonyms: RP 52028)

カタログ番号GC16569

PK 11195 (RP 52028) は、リーシュマニア化学療法を標的とするトランスロケータータンパク質 (TSPO) のリガンドであり、L の IC50 は 14.2 μM、8.2 μM、3.5 μM です。

Products are for research use only. Not for human use. We do not sell to patients.

PK 11195 化学構造

Cas No.: 85532-75-8

サイズ 価格 在庫数 個数
10 mM * 1 mL in DMSO
$55.00
在庫あり
5mg
$50.00
在庫あり
10mg
$68.00
在庫あり
50mg
$225.00
在庫あり
100mg
$405.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

PK 11195 (RP 52028) is a ligand of translocator protein (TSPO), which targets Leishmania chemotherapy, with IC50s of 14.2 μM, 8.2 μM, 3.5 μM for L. amazonensis, L. major and L. braziliensis, respectively.

Median IC50 values for PK 11195 are 14.2 μM for L. amazonensis, 8.2 μM for L. major, and 3.5 μM for L. braziliensis. The selective index value for L. amazonensis is 13.7, indicating the safety of PK 11195 for future testing in mammals. Time-and dose-dependent reductions in the percentage of infected macrophages, the number of parasites per infected macrophage, and the number of viable intracellular parasites are observed. Electron microscopy reveals some morphological alterations suggestive of autophagy. Interestingly, MCP-1 and superoxide levels are reduced in L. amazonensis-infected macrophages treated with PK 11195[1].

References:
[1]. Guedes CES, et al. In vitro evaluation of the anti-leishmanial activity and toxicity of PK-11195. Mem Inst Oswaldo Cruz. 2018 Feb 5;113(4):e170345.

レビュー

Review for PK 11195

Average Rating: 5 ★★★★★ (Based on Reviews and 14 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PK 11195

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.